Clinuvel Pharmaceuticals Limited · ASX:CUV

Clinuvel Pharmaceuticals — Investor Presentation (April 2008)

18 slides from Clinuvel Pharmaceuticals's investor presentation, Apr 18, 2008

  1. Slide 1: Strategy to market following 28 months of focus

    Clinuvel Clinuvel Pharmaceuticals Ltd For personal use only Strategy to market following 28 months of focus Leadership in photo protection April 2008 ASX: CUV Ph Wolgen, CEO XETRA-DAX: UR9 B Shanahan, Non-Exec Chair C Mackie, Head of Corporate Development ADR CLVLY

  2. Slide 2: Safe Harbour Statement

    Clinuvel Clinuvel Pharmaceuticals Ltd For personal use only SAFE HARBOUR STATEMENT Clinuvel is an Australian biopharmaceutical company focused on developing its leading drug candidate, CUV1647, for a range of UV-related skin disorders resulting from exposure of the skin to harmful UV radiation. Phar

  3. Slide 3: For personal use only

    For personal use only Clinuvel • Technological advancement January 2006 – April 2008 • Corporate performance Financials • Route to market 2008 - 2009 Meticulous project planning Challenges Innovation

  4. Slide 4: Premise 2006

    For personal use only Premise 2006 Clinuvel Establish SAFETY drug CUV1647 biological function of skin’s melanin medical benefit(s)

  5. Slide 5: Advancement 2006-2008

    For personal use only Advancement 2006 -2008 Clinuvel 1. Restructure Company, redesign clinical program First-in-Class Drug 2. Seek endorsement regulatory pathway 3. IP multiple indications (5) for 1 peptide, CUV1647 = “internal diversification” 4. Funding CUV AUD $67M to complete pharmaceutical dev

  6. Slide 6: Shift to medical program 2006-2008

    Shift to medical program 2006 -2008 Clinuvel Status Clinical Program For personal use only Phase II results UV damage (n= 65) p<0.001 MD Phase II results pharmacokinetic/-dynamic (n= 18) Plasma levels Phase II results PLE (n= 26) p< 0.01 Cortico Phase II results EPP (n= 5) p=0.007 UV-exposure Phase

  7. Slide 7: Corporate Performance 2006-2008

    Corporate Performance 2006 -2008 Clinuvel Equity Value Drivers in 28 months For personal use only 27 positive ASX announcements Funding to CUV Stability share register First regulatory acknowledgement 4th March 2008: EMEA grant of 2 Orphan Designations CUV1647

  8. Slide 8: Net Operating Cashflow

    Operating Cashflow ForNetpersonal use$m only -$4.5 -$4.0 -$3.5 -$3.0 -$2.5 -$2.0 -$1.5 -$1.0 -$0.5 $0.0 Dec-03 Mar-04 Financials Jun-04 Sep-04 Dec-04 Mar-05 Jun-05 Sep-05 Dec-05 Mar-06 Jun-06 Sep-06 Dec-06 Net Operating Cash Flow Mar-07 Jun-07 Sep-07 Dec-07 Clinuvel

  9. Slide 9: Capitalization

    Financials Clinuvel Capitalization For personal use only AUD$m $300 Cash $250 $200 $150 $100 $50 $0 Jun-01 Jun-02 Jun-03 Jun-04 Jun-05 Jun-06 Jun-07 Apr-08

  10. Slide 10: Market performance

    Market performance Clinuvel Close $1.40 For personal use only EPT1647 Lifestyle use CUV1647 Medicinal use $1.20 $1.00 Share price AUD$ $0.80 $0.60 $0.40 $0.20 Equity Effectors = Value Drivers $0.00 Aug-01 Aug-02 Aug-03 Aug-04 Aug-05 Aug-06 Aug-07 Feb-01 Feb-02 Feb-03 Feb-04 Feb-05 Feb-06 Feb-07 Feb-

  11. Slide 11: Financials shareholders base

    Financials shareholders base Clinuvel 100% Balance For personal use only 90% Custodians & 80% Nominees 70% Brokers 60% ADRs Register 50% Related Parties 40% 30% Private Investors 20% Corporates 10% Institutions 0% 2004 2005 2006 2007 2008 Source: Thomson Year

  12. Slide 12: Investor base

    Financials Clinuvel INVESTOR BASE 2004 2005 2006 2007 2008 For personal use only Institutions 3% 10% 14% 39% 36% Corporate 0% 1% 4% 4% 4% Private Investors 11% 12% 18% 15% 18% Related Parties 31% 20% 8% 1% 1% ADRs 0% 3% 4% 3% 3% Brokers 7% 8% 6% 5% 5% Custodians & Nominees 2% 5% 8% 12% 9% Balance 46

  13. Slide 13: Summary Financials

    Summary Financials Clinuvel Share capital 302M o/s For personal use only Share Capital F/D 319M o/s MCAP AUD$110M Cash burn < AUD$1M Funds AUD$53M Beta 1.48 Risk-adjusted value** AUD$1.00- 1.20 **ABNAMRO, Intersuisse

  14. Slide 14: Value Drivers 2008

    Value Drivers 2008 For personal use only Clinuvel 16 Nov’ 07 1 Jan’ 08 Mar’ 08 July’ 08 1 Oct’ 08 1 Dec ‘08 1 Jan’ 09 AGM - 2 x Orphan Drug Designations from EMEA - WHO Generic name CUV1647 AGM - Brand name CUV1647 - Start SCC Ph II RMH (Melbourne) - Start EPP Ph II US - Start PDT Ph II US - Start S

  15. Slide 15: Route to market in EU/Aus/Sui

    Clinuvel Route to market in EU/Aus/Sui For personal use only Medical Phase II Results Phase III Marketing Drug indications Phase II Authorization Registration Application ODD ODD EPP 2009 sun intolerance PLE 2010 sun poisoning AK 2010-2011 precursor to skin cancer SU anaphylactic reaction to sun PDT

  16. Slide 16: Intelligence in pharmaceutical communication

    For personal use only Intelligence in pharmaceutical communication: Launch May 2008 Clinuvel

  17. Slide 17: Conclusions

    Clinuvel Pharmaceuticals Ltd Clinuvel Conclusions For personal use only • Disruptive technology CUV1647 SAFETY, medical benefits IP continuous innovation, r&D • Clinical and regulatory progress 2 Orphan Drug Designations EMEA • Strong market support communicate during Downturn • Execution and uncond

  18. Slide 18: Thank you for your support in current markets

    Clinuvel Clinuvel Pharmaceuticals Ltd For personal use only Leadership in photo protection Thank you for your support in current markets April 2008 ASX: CUV Ph Wolgen, CEO XETRA-DAX: UR9 B Shanahan, Non-Exec Chair C Mackie, Head of Corporate Development NY: ADR1 CLVLY

Clinuvel Pharmaceuticals — Investor Presentation (April 2008) on 6ix